Indeed, increased expression of CXCL4 in tumor tissue indicated a decreased survival time in CRC patients [38], and experimental in vivo CRC models described the capacity of this chemokine to promote the proliferation and activation of Treg cells, while dampening CD8+ T cell-mediated antitumor immune responses [39]. The gene discussed is CD8A; the disease is neoplasm.